Cullinan Associates Inc. decreased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 34.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,150 shares of the medical research company’s stock after selling 17,300 shares during the period. Cullinan Associates Inc.’s holdings in Agilent Technologies were worth $1,966,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of A. Cribstone Capital Management LLC increased its stake in shares of Agilent Technologies by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 2,359 shares of the medical research company’s stock valued at $125,000 after buying an additional 54 shares in the last quarter. Trust Co. of Vermont increased its stake in shares of Agilent Technologies by 8.1% in the first quarter. Trust Co. of Vermont now owns 2,743 shares of the medical research company’s stock valued at $145,000 after buying an additional 205 shares in the last quarter. CENTRAL TRUST Co increased its stake in shares of Agilent Technologies by 15.3% in the first quarter. CENTRAL TRUST Co now owns 2,994 shares of the medical research company’s stock valued at $158,000 after buying an additional 398 shares in the last quarter. Penserra Capital Management LLC increased its stake in shares of Agilent Technologies by 9.5% in the first quarter. Penserra Capital Management LLC now owns 3,496 shares of the medical research company’s stock valued at $184,000 after buying an additional 304 shares in the last quarter. Finally, Coconut Grove Bank increased its stake in shares of Agilent Technologies by 84.7% in the first quarter. Coconut Grove Bank now owns 3,750 shares of the medical research company’s stock valued at $198,000 after buying an additional 1,720 shares in the last quarter.

Shares of Agilent Technologies, Inc. (NYSE:A) opened at 60.13 on Monday. Agilent Technologies, Inc. has a 52-week low of $42.92 and a 52-week high of $61.84. The stock has a market capitalization of $19.32 billion, a PE ratio of 33.80 and a beta of 1.30. The stock has a 50 day moving average price of $60.08 and a 200-day moving average price of $55.15.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Monday, May 22nd. The medical research company reported $0.58 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.48 by $0.10. The company had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Agilent Technologies had a return on equity of 16.49% and a net margin of 13.41%. The firm’s revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.44 earnings per share. On average, equities research analysts anticipate that Agilent Technologies, Inc. will post $2.23 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 26th. Shareholders of record on Monday, July 3rd were paid a dividend of $0.132 per share. This represents a $0.53 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend was Thursday, June 29th. Agilent Technologies’s dividend payout ratio (DPR) is currently 29.78%.

COPYRIGHT VIOLATION NOTICE: “Agilent Technologies, Inc. (NYSE:A) Shares Sold by Cullinan Associates Inc.” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/07/cullinan-associates-inc-sells-17300-shares-of-agilent-technologies-inc-nysea-updated-updated-updated.html.

A has been the subject of several research analyst reports. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 price objective for the company in a research note on Tuesday, May 16th. Deutsche Bank AG raised their price objective on Agilent Technologies from $58.00 to $62.00 and gave the stock a “buy” rating in a research note on Monday, May 22nd. Cowen and Company raised their price objective on Agilent Technologies from $53.00 to $62.00 and gave the stock a “market perform” rating in a research note on Tuesday, May 23rd. Jefferies Group LLC raised their price objective on Agilent Technologies from $59.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, May 23rd. Finally, Robert W. Baird raised their price objective on Agilent Technologies from $57.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 24th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Agilent Technologies presently has an average rating of “Buy” and a consensus target price of $60.12.

In related news, Director James Cullen sold 15,482 shares of the company’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $59.04, for a total value of $914,057.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael R. Mcmullen sold 50,000 shares of the company’s stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $59.86, for a total transaction of $2,993,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 112,608 shares of company stock worth $6,737,509.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Stock Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related stocks with our FREE daily email newsletter.